⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 1, 2021Clinical and Translational AllergyOpen Access

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

The study is registered with ClinicalTrials.gov (NCT03472040).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Farkas et al. (2021) studied this question.

synapsesocial.com/papers/69de7a917ed287395e559028 https://doi.org/10.1002/clt2.12035

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical settingOriginal Research · 2016 · 103 citations
2Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease.Qualitative Study · 2004 · 1,009 citations
3Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trialCohort Study · 2020 · 45 citations
4Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary AngioedemaRCT · 2010 · 408 citations
5Development and construct validation of the angioedema quality of life questionnaireOriginal Research · 2012 · 308 citations